[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Sağlık ve TıpOne-Off3yManifold MarketsKYC yokDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel topluluk tahmini2030 36.4%6 seçenek arasında lider
Tahminciler
21
Soru türü
multiple choice
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
7g Değişim
0.0 pts
Piyasa verileri
9 saat önce güncellendi
Guncelligini yitirmis18 Kas 23 22:14 UTC1 Oca 30 04:59 UTC
Trendler
Kurallar
Inspired by https://manifold.markets/AaronKaufman/will-any-fdaapproved-glp1-agonists and will use the same criteria:
- GLP-1 agonists, such as semaglutide (ozempic/wegovy), tirzepatide (mounjaro), and dulaglutide (Trulicity), are becoming popular for weight loss and Type-2 diabetes treatment.
- This market resolves positively if any approved GLP-1 agonists for either T2D or weight loss are withdrawn from the market due to safety reasons by the listed date.
- This applies either if the FDA mandates it or if the company withdraws the drug voluntarily.
